| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HNRNPA2B1 |
| Uniprot No | P22626 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-353aa |
| 氨基酸序列 | MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKRSRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIKEDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGHNAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGFGDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNYNDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY |
| 预测分子量 | 44.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HNRNPA2B1重组蛋白的3篇代表性文献摘要概括(基于真实研究领域方向，具体文献标题和作者为模拟示例)：
---
1. **文献名称**：*HNRNPA2B1 regulates mRNA splicing and stability during cellular stress*
**作者**：Smith J, et al.
**摘要**：通过重组HNRNPA2B1蛋白的体外结合实验，揭示了其通过识别特定RNA基序调控mRNA选择性剪接的机制，并发现其在DNA损伤应激下通过相分离促进mRNA稳定性的新功能。
2. **文献名称**：*Phase separation of HNRNPA2B1 promotes antiviral immune response*
**作者**：Li X, et al.
**摘要**：利用重组HNRNPA2B1蛋白进行体外相分离实验，证明其通过液-液相分离聚集病毒RNA，激活MAVS信号通路以增强I型干扰素表达，揭示了其在抗病毒天然免疫中的关键作用。
3. **文献名称**：*HNRNPA2B1 promotes cancer metastasis via exosomal RNA packaging*
**作者**：Wang Y, et al.
**摘要**：通过重组HNRNPA2B1蛋白与RNA的互作研究，发现其通过结合特定microRNA前体(如miR-19a)，调控肿瘤外泌体RNA的包装过程，进而促进乳腺癌转移的分子机制。
---
**备注**：以上文献为示例，实际研究中可检索PubMed等数据库获取具体文献(关键词：HNRNPA2B1 recombinant protein/splicing/phase separation/cancer)。该蛋白的研究热点多聚焦于RNA代谢调控、相分离病理机制及癌症/神经退行性疾病关联。
HNRNPA2B1 is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, which plays critical roles in RNA metabolism, including splicing, transport, stability, and translation regulation. As an RNA-binding protein, HNRNPA2B1 recognizes specific sequences or structures in target RNAs, influencing gene expression at multiple levels. It is ubiquitously expressed and localizes predominantly to the nucleus, though it shuttles between nuclear and cytoplasmic compartments to fulfill diverse functions. Recombinant HNRNPA2B1 protein is commonly produced in *E. coli* or mammalian expression systems, often fused with tags like His-tag for purification. This engineered protein retains native binding activity, enabling *in vitro* studies to dissect its molecular interactions, post-translational modifications, and regulatory mechanisms.
Research on HNRNPA2B1 has gained momentum due to its involvement in human diseases. Mutations in HNRNPA2B1 are linked to neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and inclusion body myopathy (IBM), where aberrant protein aggregation disrupts RNA homeostasis and stress granule dynamics. Additionally, HNRNPA2B1 is implicated in cancer, where it regulates oncogenic transcripts to promote proliferation, metastasis, and immune evasion. Its overexpression in malignancies like breast cancer and glioma highlights its potential as a diagnostic marker or therapeutic target. Recombinant variants, including disease-associated mutants (e.g., D290V), are instrumental in modeling pathogenesis and screening drug candidates. Structurally, HNRNPA2B1 contains two RNA recognition motifs (RRMs) and a low-complexity domain prone to liquid-liquid phase separation—a property critical for its role in membraneless organelles. Studies using recombinant proteins continue to unravel its dual roles in maintaining cellular homeostasis and driving disease pathways.
×
